

Ein cyf/Our ref: AWMSG to Oct 2013 [3]

Gofynnwch am/Please ask for: Sue Beach Rhif Ffôn /Telephone: 01554 783462

Ffacs/Facsimile:

E-bost/E-mail: sue.beach@wales.nhs.uk

Dr Carol Llewellyn-Jones Glangwili General Hospital Dolgwili Road, Carmarthen, Carmarthenshire, SA31 2AF Tel: 01267 235151

Dr Carol Llewellyn-Jones Ysbyty Cyffredinol Glangwili Heol Dolgwili, Caerfyrddin

Sir Gaerfyrddin, SA31 2AF Rhif Ffôn: 01267 235151

**DATE 28.11.13 BY EMAIL** Page 1 of 3

TO: All prescribers
County lead pharmacists
Assistant Director of Nursing (Practice)
Hywel Dda Health Board global email

Dear Colleague

The appraisals listed below have been published by the All Wales Medicines Strategy Group (AWMSG). They have been assessed for local implementation and their place in therapy established as described.

### Please ensure that your teams are fully aware of this information.

In accordance with the provisions of Welsh Ministerial Letter ML/009 /09 (see EH/ML/009/09: <a href="http://www.wales.nhs.uk/documents/EH-ML-009-09.pdf">http://www.wales.nhs.uk/documents/EH-ML-009-09.pdf</a>, 19.3.09), these drugs are being added to the Health Board's formulary, <a href="http://hywelddahb.inform.wales.nhs.uk/">http://hywelddahb.inform.wales.nhs.uk/</a>, and will be available for prescribing in accordance with the guidance.

Please ensure that the appropriate audit forms are completed for all initiations on these therapies in the next 12 months. You will find the audit forms on the Clinical Systems (NICE / TA AWMSG appraisal audits) pages of the Health Board's Intranet: http://howis.wales.nhs.uk/sitesplus/862/page/43199

Pharmacy has been notified of the guidance and you should be aware that prescriptions that fall outside the recommendations of AWMSG guidance will be discussed with prescribers before dispensing. Please note that failure to complete the appropriate audit form may result in a delay in dispensing.

# AWMSG 2712/763 Eplerenone (Inspra®)

http://www.awmsg.org/awmsgonline/app/appraisalinfo/763

Approved for use in NYHA Class II (chronic) Heart Failure with LVEF<30%.

#### AWMSG 0613/1715 Aztreonam lysine (Cayston®)

http://www.awmsg.org/awmsgonline/app/appraisalinfo/1715

Approved for use by Consultants specialising in treating Cystic Fibrosis (Hospital Only).

Pencadlys Bwrdd Iechyd Hywel Dda Llys Myrddin, Lôn Winch, Hwlffordd, Sir Benfro, SA61 1SB Rhif Ffôn: (01437) 771220 Rhif Ffacs: (01437) 771222 Hywel Dda Health Board Headquarters Merlins Court, Winch Lane, Haverfordwest, Pembrokeshire, SA61 1SB Tel Nr: (01437) 771220 Fax Nr: (01437) 771222 Cadeirydd / Chairman Mr Chris Martin

Prif Weithredwr / Chief Executive Yr Athro/Professor Trevor Purt

#### AWMSG 0713/1455 Glycopyrronium bromide (Seebr Breezhaler®)

http://www.awmsg.org/awmsgonline/app/appraisalinfo/1455

Approved for adding to formulary as an alternative to tiotropium. Position to be determined in the Respiratory review.

### AWMSG 0813/938 Aclidinium bromide (Eklira® Genuair®)

http://www.awmsg.org/awmsgonline/app/appraisalinfo/938

Approved for adding to formulary as an alternative to tiotropium. Position to be determined in the Respiratory review

#### AWMSG 0913/145 Ferumoxytol (Rienso®)

http://www.awmsg.org/awmsgonline/app/appraisalinfo/145

Approved for Specialist and Hospital Use only as advised by ABMU Renal Unit and Consultants

#### AWMSG 1013/1392 Ingenol mebutate (Picato®)

http://www.awmsg.org/awmsgonline/app/appraisalinfo/1065

Approved for Dermatology consultants and GPwSI use only. Second line use after Fluorouracil cream. GPwSI Dermatology only may prescribe using WP10.

### **AWMSG 1113/1681 Linagliptin/metformin (Jentadueto®)**

http://www.awmsg.org/awmsgonline/app/appraisalinfo/1681

Approved for 2nd line including GP use as per Linagliptin.

### AWMSG 1213/1383 Darunavir (Prezista®)

http://www.awmsg.org/awmsgonline/app/appraisalinfo/1383

Approved for Specialist and Hospital use only.

#### **AWMSG 1313/1219 Perampanel (Fycompa®)**

http://www.awmsg.org/awmsgonline/app/appraisalinfo/1219

Approved for Specialist and Hospital use only for complex seizures in patients with epilepsy.

### AWMSG 1413/1065 Ceftaroline fosamil (Zinforo®)

http://www.awmsq.org/awmsgonline/app/appraisalinfo/1065

Approved for use on Consultant Microbiologist advice only. Hospital or ART use only.

#### AWMSG 1513/1381 Adalimumab (Humira®)

[Adults with severe axial spondyloarthritis]

http://www.awmsg.org/awmsgonline/app/appraisalinfo/1381

Approved for Specialist and Hospital use only.

### AWMSG 1613/1425 C1-Esterase inhibitor (Berinert®)

http://www.awmsg.org/awmsgonline/app/appraisalinfo/1425

Approved for Specialist use for the treatment of acute treatment of acute episodes of hereditary angioedema type I and II. NB Berinert® is not recommended for the pre-procedure prevention of acute episodes of hereditary angioedema type I and II (HAE) in the absence of a submission from the manufacturer.

### AWMSG 1713/178 Lapatinib (Tyverb®)

http://www.awmsg.org/awmsgonline/app/appraisalinfo/178

Approved for Specialist use (Hospital only) in line with the South Wales Cancer Network Breast Cancer treatment Guidelines May 2013 ABMU and Hywel Dda accessed at <a href="http://howis.wales.nhs.uk/sites3/Documents/983/Breast%20Cancer%20Treatment%20Guidelines%20">http://howis.wales.nhs.uk/sites3/Documents/983/Breast%20Cancer%20Treatment%20Guidelines%20</a> %20ABMU%20and%20Hywel%20Dda%20May%2020131.pdf

## AWMSG 1913/1575 Ulipristal acetate (Esmya®)

http://www.awmsq.org/awmsgonline/app/appraisalinfo/1575

Approved for Specialist and Hospital use only. Full 3 month course to be supplied from hospital.

### AWMSG 2013/749 Adalimumab (Humira®)

[Crohn's disease in paediatric patients (6 to 17 yrs of age)] http://www.awmsg.org/awmsgonline/app/appraisalinfo/749 Approved for Specialist and Hospital use only

#### AWMSG 2113/1977 Adalimumab (Humira®)

[Polyarticular juvenile idiopathic arthritis, in children aged 2 to 4 years] http://www.awmsg.org/awmsgonline/app/appraisalinfo/1977 Approved for Specialist and Hospital use only

### **AWMSG 2213/1643 Tenofovir disoproxil fumarate (Viread®)**

[HIV-1-infected adolescent and paediatric patients] http://www.awmsg.org/awmsgonline/app/appraisalinfo/1643 Approved for Specialist and Hospital use only

### AWMSG 2313/1880 Tenofovir disoproxil fumarate (Viread®)

[Chronic hepatitis B in adolescents 12 to < 18 years of age] http://www.awmsg.org/awmsgonline/app/appraisalinfo/1880 Approved for Specialist and Hospital use only

If you have any questions relating to the guidance or this process, please contact Sue Beach, Lead Clinical Development Pharmacist, on 01554 783084; email <a href="mailto:sue.beach@wales.nhs.uk">sue.beach@wales.nhs.uk</a>.

Dr Carol Llewellyn-Jones Consultant Physician Chairman, Medicines Management Group

AMD Carmarthenshire